Northwestern Health Sciences University

Fulcrum Health welcomes two members to its Board of Directors

Retrieved on: 
Tuesday, March 29, 2022
Health, LinkedIn, Leadership, NCQA, Clinical Excellence Awards, Patient satisfaction, Board, Chiropractic, Robert J. Anderson (public health administrator), M Health Fairview, MPH, Acupuncture, Board of directors, Pain management, Bethel University, Quality of life, University, Business administration, University of Minnesota Duluth, Penny George Institute for Health and Healing, North Memorial Health Hospital, Northwestern Health Sciences University, Management, Medicine, Healthcare, Fulcrum, Allina Health, CPA

PLYMOUTH, Minn., March 29, 2022  /PRNewswire-PRWeb/ -- Fulcrum Health, Inc., a nonprofit physical medicine benefit management organization, announced today that it has added two new members to its Board of Directors. Dan Fromm, CPA, MPH, and Steve Dandrea, D.C., FIANM, join Fulcrum's Board as it continues to guide the organization in achieving its vision to be the leader in high-quality physical medicine networks.

Key Points: 
  • "We are fortunate to have the support and guidance of these leading healthcare experts who are dedicated to helping us fulfill our mission," said Patricia Dennis, Fulcrum Health CEO and Board member.
  • Dan Fromm, who will serve as treasurer of Fulcrum's Board, is chief financial officer at North Memorial Health.
  • The new Fulcrum Health Board members join an impressive slate of practicing clinical experts, as well as business and healthcare leaders, including:
    Departing the Board are Mark Bortnem, past vice president of finance, shared clinical services at Fairview Health Services, and Leo Bronston, D.C., owner of Bronston Chiropractic.
  • Fulcrum Health is a multiple year recipient of the Press Ganey Guardian of Excellence Award for outstanding performance in patient satisfaction.

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
Nasdaq, AACR, Clinical trial, American Association for Cancer Research, Twitter, Large-cell lung carcinoma, Drug development, TRK, Risk, Private Securities Litigation Reform Act, Company, OR, Research, U.S. Securities and Exchange Commission, Tropomyosin, Cancer, Northwestern Health Sciences University, Mutation, Date, CNS, Chemistry, Multimedia, Brain, Neuroblastoma, Oregon Health and Science University Center for Women's Health, Patient, Health, Security (finance), American Association, B-cell lymphoma, ROS1, COVID-19, Neoplasm, Time, Association, CT, ALK, NSCLC, LinkedIn, Pharmaceutical industry, Communications satellite

Data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 from April 8-13 in New Orleans.

Key Points: 
  • Data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 from April 8-13 in New Orleans.
  • NVL-520 is currently under investigation in the Phase 1/2 ARROS-1 study ( NCT05118789 ) for advanced ROS1-positive NSCLC and other solid tumors, including those with resistance mutations.
  • The second poster characterizes NVL-655 alongside other ALK inhibitors in ALK-driven cancer models beyond NSCLC such as anaplastic large cell lymphoma and neuroblastoma.
  • A Phase 1/2 clinical trial of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors is planned for the first half of 2022.

Vibrant submits innovative non-drug chronic idiopathic constipation treatment for FDA clearance

Retrieved on: 
Friday, December 17, 2021
Circadian rhythm, Constipation, Phase, Food, Gastrointestinal tract, OTC, FDA, Vibrant consonant, ENS, Life, Northwestern Health Sciences University, Sale, III, Harvard Medical School, CIC, Medical college, Science, University of Michigan, Review, Enteric nervous system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Safety, Patient, Gut–brain axis, Houston Methodist Hospital, Medicine, Augusta University, University, Classification, Medical College of Georgia, Defecation, Pharmaceutical industry, Medical device, Dietary supplement, Laxative

NEW YORK, Dec. 17, 2021 /PRNewswire-PRWeb/ --Vibrant has announced that the Vibrant System for chronic idiopathic constipation met its primary safety and efficacy endpoints in the V-270 pivotal trial.

Key Points: 
  • NEW YORK, Dec. 17, 2021 /PRNewswire-PRWeb/ --Vibrant has announced that the Vibrant System for chronic idiopathic constipation met its primary safety and efficacy endpoints in the V-270 pivotal trial.
  • "The goal of Vibrant is to address a real problem in chronic constipation, which has made life very challenging for those who suffer from it.
  • The new Vibrant non-drug system provides new hope to the millions of Americans who suffer from chronic idiopathic constipation without satisfactory relief from Laxatives.
  • Vibrant is a proprietary, biocompatible treatment for chronic idiopathic constipation (CIC).

Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Retrieved on: 
Thursday, December 9, 2021
EMA, U.S. Securities and Exchange Commission, LCA, Lists of diseases, Risk, Rhodopsin, Research, Retina, GLOBE, SEC, Oregon Health & Science University, Private Securities Litigation Reform Act, Security (finance), Investigational New Drug, Mutation, NR2E3, Safety, Gene, Food, Patient, Leber congenital amaurosis, Retinitis pigmentosa, Vaccine, Drug discovery, Diabetic retinopathy, Board, MD, European Medicines Agency, COVID-19, Clinical trial, FDA, RP, Northwestern Health Sciences University, NASDAQ, AAV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, Health Canada, MBA, IND, Pharmaceutical industry

Were collaborating with leading centers in eye care and have been vital partners to getting our trial launched and receive patients.

Key Points: 
  • Were collaborating with leading centers in eye care and have been vital partners to getting our trial launched and receive patients.
  • With this final decision by the FDA, we are embarking on a new pathway of care through this innovative gene therapy.
  • Traditional gene therapy, which transfers a functional version of a non-functional gene into target cells, targets only one individual gene mutation at a time.
  • OCU400 was granted four orphan drug disease designations from the FDA for treating four different gene mutation-associated retinal degenerative diseases between 2019 and 2020.

Independent, Not-for-profit Air Ambulance Programs Life Flight Network and Life Link III to Partner on Safety, Quality, Training and Advocacy

Retrieved on: 
Wednesday, December 8, 2021
Aurora, Essentia, Commission on Accreditation of Medical Transport Systems, Commission, Helicopter Association International, Providence Health & Services, Health, Essentia Health, Growth, Letter, Legacy Health, Oregon Health & Science University, Safety, Record, Willmar, Minnesota, HAI, Patient, CEO, Organization, Critical care, CentraCare Health, Life Flight Network, Accreditation, Multimedia, Pacific Northwest, Program, CAMTS, Atmosphere, Association, Air medical services, Human, AAMS, Allina Health, Northwestern Health Sciences University, Airline, Health insurance, Pharmaceutical industry

BLOOMINGTON, Minn. and AURORA, Ore., Dec. 8, 2021 /PRNewswire/ -- Two independent, hospital-owned, not-for-profit air ambulance programs, Life Flight Network and Life Link III, today announced the signing of a letter of intent to launch a strategic alliance. This alliance will bring the organizations together to collaborate on best practices, process improvement, quality initiatives, and safety, all with a focus on the patients and communities they serve.

Key Points: 
  • BLOOMINGTON, Minn. and AURORA, Ore., Dec. 8, 2021 /PRNewswire/ --Two independent, hospital-owned, not-for-profit air ambulance programs, Life Flight Network and Life Link III, today announced the signing of a letter of intent to launch a strategic alliance.
  • Life Flight Network and Life Link III are similarly structured air medical consortiums, with each program utilizing similar onboard medical equipment and operating many of the same aircraft models.
  • "Life Link III and Life Flight Network are respected, industry-leading programs who share an unwavering commitment to strong cultures of safety and exceedingly high excellence in patient care," said Josh Howell, Life Link III's CEO.
  • Both organizations have been honored as Program of the Year by the Association of Air Medical Services (AAMS), with Life Link III being honored in 2017 and Life Flight Network in 2009 and 2021.

OCHIN Joins NIH Funded AI/ML Consortium to Advance Health Equity and Researcher Diversity

Retrieved on: 
Thursday, October 7, 2021
Data, Patient-Centered Outcomes Research Institute, Technology, Program, National, Health equity, University of North Texas Health Science Center, Machine learning, Goal, University of California, Oregon Health & Science University, Multimedia, Public health, Racism, Fenway Health, Industry, Research, Artificial intelligence, Northwestern Health Sciences University, North Carolina Central University, Health, University, Gaps, Data science, EHR, Central University, CEO, PCORI, NIH, Morehouse School of Medicine, Partnership, Patient, View, Bias, Medical device, Medicine

PORTLAND, Ore., Oct. 7, 2021 /PRNewswire/ -- OCHIN, a national nonprofit learning network for health equity research and innovation, has been selected to lead the data and research component of the National Institutes of Health (NIH) AIM-AHEAD program , a new artificial intelligence and machine learning consortium to advance health equity and researcher diversity.

Key Points: 
  • PORTLAND, Ore., Oct. 7, 2021 /PRNewswire/ -- OCHIN, a national nonprofit learning network for health equity research and innovation, has been selected to lead the data and research component of the National Institutes of Health (NIH) AIM-AHEAD program , a new artificial intelligence and machine learning consortium to advance health equity and researcher diversity.
  • Left unaddressed, these gaps threaten to exacerbate bias, racism, and inequity in the health care system, widening national health disparities.
  • "We're proud to support this important NIH initiative because we believe that technology can, and should, drive equitable health care innovation," said Abby Sears, CEO of OCHIN.
  • ADVANCE is a multicenter research network led by OCHIN in partnership with Fenway Health, Health Choice Network, and Oregon Health & Science University.

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration

Retrieved on: 
Tuesday, September 28, 2021
Oregon Health & Science University, Biotechnology, CNS, Harvard Medical School, Retina, Food, Assistant, Severe cognitive impairment, ACHM, Annual report, OCT, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Retinal degeneration, Applied Genetic Technologies Corporation, Central nervous system disease, Therapy, Optogenetics, CNGA3, Patient, Retinitis pigmentosa, Tunnel, MD, Central nervous system, Optical coherence tomography, Form 10-K, Gene, CEO, CNGB3, LLC, COVID-19, Technology, Drug development, Neurotology, Color, Forward-looking statement, Safety, Northwestern Health Sciences University, Pediatrics, AAV, Doctor of Philosophy, Nasdaq, GLOBE, Pharmaceutical industry

The sustained durability of improved visual function over 12 months is compelling evidence of biological activity for this XLRP gene therapy.

Key Points: 
  • The sustained durability of improved visual function over 12 months is compelling evidence of biological activity for this XLRP gene therapy.
  • AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHMB3 and ACHMA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting

Retrieved on: 
Tuesday, September 7, 2021

The results are being presented in a Late Breaking Clinical Trials session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting on September 12, 2021.

Key Points: 
  • The results are being presented in a Late Breaking Clinical Trials session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting on September 12, 2021.
  • The conference call will be simultaneously webcast and will be accessible in the Investors & Media section of Cytokinetics website at www.cytokinetics.com .
  • An archived replay of the webcast will be available via Cytokinetics' website until September 27, 2021.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Anatomy, Medical specialties, Blood, Hematology, Cardiovascular physiology, Blood volume, Transfusion medicine, Intravascular volume status, Blood test, Blood plasma, Capillary

Oak Ridge, TN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data published in the journal Critical Care showing Daxor’s unique BVA-100 diagnostic blood test provides insights into the pathophysiology of volume derangements and capillary distress in critically ill COVID-19 patients enabling improved care.

Key Points: 
  • The Research Letter titled Blood volume and albumin transudation in critically-ill COVID-19 patients studied the abnormal blood volume profiles in mechanically ventilated patients admitted to the ICU at a leading medical center in New York.
  • The data shows that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of through the use of the Daxor BVA-100 blood test.
  • Daxors BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients blood volume with a 98% accurate measure of plasma and red cell volume.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.